Literature DB >> 17463288

Modeling the initiation and progression of human acute leukemia in mice.

Frédéric Barabé1, James A Kennedy, Kristin J Hope, John E Dick.   

Abstract

Our understanding of leukemia development and progression has been hampered by the lack of in vivo models in which disease is initiated from primary human hematopoietic cells. We showed that upon transplantation into immunodeficient mice, primitive human hematopoietic cells expressing a mixed-lineage leukemia (MLL) fusion gene generated myeloid or lymphoid acute leukemias, with features that recapitulated human diseases. Analysis of serially transplanted mice revealed that the disease is sustained by leukemia-initiating cells (L-ICs) that have evolved over time from a primitive cell type with a germline immunoglobulin heavy chain (IgH) gene configuration to a cell type containing rearranged IgH genes. The L-ICs retained both myeloid and lymphoid lineage potential and remained responsive to microenvironmental cues. The properties of these cells provide a biological basis for several clinical hallmarks of MLL leukemias.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17463288     DOI: 10.1126/science.1139851

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  138 in total

Review 1.  Epigenetics in myelodysplastic syndromes.

Authors:  Michael Heuser; Haiyang Yun; Felicitas Thol
Journal:  Semin Cancer Biol       Date:  2017-08-02       Impact factor: 15.707

2.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

3.  Controversies in cancer stem cells: targeting embryonic signaling pathways.

Authors:  Naoko Takebe; S Percy Ivy
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

4.  MLL-ENL leukemia burden initiated in femoral diaphysis and preceded by mature B-cell depletion.

Authors:  Agnieszka Jaracz-Ros; Daniel Lewandowski; Vilma Barroca; Catherine Lavau; Paul-Henri Roméo
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 5.  Cancer stem cell hypotheses: impact on modern molecular physiology and pharmacology research.

Authors:  Igor Pantic
Journal:  J Biosci       Date:  2011-12       Impact factor: 1.826

Review 6.  The molecular pathology of breast cancer progression.

Authors:  Alessandro Bombonati; Dennis C Sgroi
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

7.  Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs.

Authors:  Vikas Tyagi; Hanan Alwaseem; Kristen M O'Dwyer; Jessica Ponder; Qi Ying Li; Craig T Jordan; Rudi Fasan
Journal:  Bioorg Med Chem       Date:  2016-06-16       Impact factor: 3.641

8.  MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.

Authors:  Corina Buechele; Erin H Breese; Dominik Schneidawind; Chiou-Hong Lin; Johan Jeong; Jesus Duque-Afonso; Stephen H K Wong; Kevin S Smith; Robert S Negrin; Matthew Porteus; Michael L Cleary
Journal:  Blood       Date:  2015-08-26       Impact factor: 22.113

9.  Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia.

Authors:  Yi Zhang; Kristina Owens; Layla Hatem; Carolyn H Glass; Kannan Karuppaiah; Fernando Camargo; Archibald S Perkins
Journal:  Blood       Date:  2013-09-10       Impact factor: 22.113

10.  Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.

Authors:  Wenyu Yu; Emma J Chory; Amy K Wernimont; Wolfram Tempel; Alex Scopton; Alexander Federation; Jason J Marineau; Jun Qi; Dalia Barsyte-Lovejoy; Joanna Yi; Richard Marcellus; Roxana E Iacob; John R Engen; Carly Griffin; Ahmed Aman; Erno Wienholds; Fengling Li; Javier Pineda; Guillermina Estiu; Tatiana Shatseva; Taraneh Hajian; Rima Al-Awar; John E Dick; Masoud Vedadi; Peter J Brown; Cheryl H Arrowsmith; James E Bradner; Matthieu Schapira
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.